Jonas Oldgren

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts

Sundh, Josefin; Parker, William A. E.; Oldgren, Jonas; Andell, Pontus et al.

Part of The International Journal of Chronic Obstructive Pulmonary Disease, p. 1-11, 2026

DOI for Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts
Download full text (pdf) of Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts

Early versus delayed DOAC after ischaemic stroke in atrial fibrillation: 1-year outcomes in the TIMING study and in concurrent practice

Fasth, Oskar; Oldgren, Jonas; Ghukasyan Lakic, Tatevik; Hijazi, Ziad et al.

Part of European Stroke Journal, 2026

Evaluation of the updated ABC-AF-bleeding score 2.0 in patients with atrial fibrillation treated with a direct oral anticoagulant or warfarin

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Alexander, John H. et al.

Part of Journal of Thrombosis and Haemostasis, p. 399-407, 2026

Coronary Computed Tomography Angiography in Prediction of First Coronary Events

Bergström, Göran; Engström, Gunnar; Björnson, Elias; Adiels, Martin et al.

Part of Journal of the American Medical Association (JAMA), p. 245-254, 2026

DOI for Coronary Computed Tomography Angiography in Prediction of First Coronary Events

Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure

Pol, Tymon; Lindbäck, Johan; Oldgren, Jonas; Alexander, John H. et al.

Part of Journal of the American Heart Association, 2026

Systolic inter-arm blood pressure difference and subclinical atherosclerosis: a population-based cohort study of 29 921 individuals

Gottsäter, Anders; Dakhel, Ardwan; Acosta, Stefan; Andell, Pontus et al.

Part of Journal of Hypertension, p. 346-353, 2026

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Oldgren, Jonas; Hijazi, Ziad; Arheden, Hakan; Bjorkenheim, Anna et al.

Part of Circulation, p. 1457-1469, 2025

Correction: Large simple randomized controlled trials-from drugs to medical devices

Buccheri, Sergio; James, Stefan; Mafham, Marion; Landray, Martin et al.

Part of Trials, p. 80, 2025

DOI for Correction: Large simple randomized controlled trials-from drugs to medical devices

Prevalence and prediction of masked uncontrolled hypertension in patients recently hospitalized for myocardial infarction

Hellqvist, Henrik; Erlinge, David; Lindahl, Bertil; Jernberg, Tomas et al.

Part of European Heart Journal Open, 2025

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Alexander, John H.; Lydon, Elizabeth J.; Piccini, Jonathan P.; Viethen, Thomas et al.

Part of JAMA cardiology, p. 555-563, 2025

DOI for Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI

Erlinge, David; James, Stefan; Deanfield, John; Eriksson, Niclas et al.

Part of ESC Heart Failure, 2025

Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

Hijazi, Ziad; Wallentin, Lars; Arheden, Hakan; Bjorkenheim, Anna et al.

Part of American Heart Journal, p. 161-169, 2025

Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial

Storey, Robert F.; Deanfield, John; James, Stefan; Ajjan, Ramzi A. et al.

Part of Journal of the American Heart Association, 2025

Associations between physical activity and CVD-related metabolomic and proteomic biomarkers

Ekblom, Örjan; Björkbacka, Harry; Börjesson, Mats; Ekblom-Bak, Elin et al.

Part of PLOS ONE, 2025

Alcohol Intake and Cardiovascular Outcomes in Patients With Atrial Fibrillation: RE-LY AF Registry Analysis

Oraii, Alireza; Conen, David; Johnson, Linda S.; McIntyre, William F. et al.

Part of Annals of Noninvasive Electrocardiology, 2025

Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study

Parker, William A. E.; Sundh, Josefin; Oldgren, Jonas; Andell, Pontus et al.

Part of BMJ Open, 2025

Asundexian versus Apixaban in Patients with Atrial Fibrillation

Piccini, Jonathan P; Patel, Manesh R; Steffel, Jan; Ferdinand, Keith et al.

Part of New England Journal of Medicine, p. 23-32, 2025

DOI for Asundexian versus Apixaban in Patients with Atrial Fibrillation

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Part of Journal of the American College of Cardiology, 2025

DOI for Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P. et al.

Part of Journal of the American Heart Association, 2025

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

James, Stefan; Erlinge, David; Storey, Robert F.; McGuire, Darren K. et al.

Part of NEJM evidence, 2024

DOI for Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

Sex differences in prevalence and characteristics of imaging-detected atherosclerosis: a population-based study

Swahn, Eva; Sederholm Lawesson, Sofia; Alfredsson, Joakim; Fredrikson, Mats et al.

Part of European Heart Journal Cardiovascular Imaging, p. 1663-1672, 2024

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

Lund, Lars H; James, Stefan; DeVore, Adam D; Anstrom, Kevin J et al.

Part of European Journal of Heart Failure, p. 2453-2463, 2024

Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial

Erlinge, David; Andersson, Jonas; Fröbert, Ole; Törnerud, Mattias et al.

Part of The Lancet, p. 1750-1759, 2024

DOI for Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial

Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

Johnson, Linda S.; Jiang, Yuxuan; Luu, Judy; Van Gelder, Isabelle C. et al.

Part of European Heart Journal, p. 2336-2340, 2024

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Gkarmiris, Konstantinos I.; Lindbäck, Johan; Alexander, John H.; Granger, Christopher B. et al.

Part of Journal of the American Heart Association, 2024

Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent

Erlinge, David; Andersson, Jonas; Froebert, Ole; Toernerud, Mattias et al.

Part of American Heart Journal, p. 1-10, 2024

Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure

James, Stefan; Storey, Robert F.; Oldgren, Jonas

Part of European Heart Journal - Cardiovascular Pharmacotherapy, p. 91-92, 2024

DOI for Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART

Rosén, Hans Christian; Mohammad, Moman A.; Jernberg, Tomas; James, Stefan et al.

Part of The Lancet Regional Health, 2024

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P et al.

Part of Circulation, p. 1090-1100, 2024

DOI for Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

Latva-Rasku, Aino; Rebelos, Eleni; Tuisku, Jouni; Aarnio, Richard et al.

Part of Diabetes Care, 2024

DOI for SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study

Patients' experiences of clinical trial participation involving a product remotely assessing study drug adherence

Henriksson, Catrin; Olsson, Anneli; Andersen, Kasper; Arefalk, Gabriel et al.

Part of Contemporary Clinical Trials Communications, 2024

Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Benz, Alexander P. et al.

Part of American Heart Journal, p. 55-63, 2023

Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Camm, A. John; Costa, Francisco et al.

Part of European Heart Journal - Quality of Care and Clinical Outcomes, p. 609-620, 2023

Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction

James, Stefan; Erlinge, David; Storey, Robert F.; Mcguire, Darren K. et al.

Part of American Heart Journal, p. 188-197, 2023

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Part of Europace, 2023

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Schnabel, Renate B; Marinelli, Elena Andreassi; Arbelo, Elena; Boriani, Giuseppe et al.

Part of Europace, p. 6-27, 2023

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Oldgren, Jonas; Åsberg, Signild; Hijazi, Ziad; Wester, Per et al.

Part of Circulation, p. 1056-1066, 2022

Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

Costa, Francesco; Valgimigli, Marco; Steg, Philippe Gabriel; Bhatt, Deepak L et al.

Part of European Heart Journal - Cardiovascular Pharmacotherapy, p. 216-226, 2022

DOI for Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

SGLT2 inhibition reduces myocardial oxygen consumption

Søndergaard, Esben; Lauritzen, Esben S; Lauritsen, Katrine M; Åkerblom, Axel et al.

Part of Metabolism Open, 2022

Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.

Mendoza, Pablo A; McIntyre, William F; Belley-Côté, Emilie P; Wang, Jia et al.

Part of Journal of Thrombosis and Thrombolysis, p. 74-82, 2022

DOI for Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.

Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

Vamos, Mate; Oldgren, Jonas; Nam, Gi-Byoung; Lip, Gregory Y. H. et al.

Part of European Heart Journal - Cardiovascular Pharmacotherapy, p. 363-371, 2022

Previous history of hyperthyroidism in emergency department patients with atrial fibrillation does not increase the risk of thromboembolism and death

Chan, Jing Jing; Lim, Swee Han; Tan, Ru San; Wang, Jia et al.

Part of Annals of the Academy of Medicine, Singapore, p. 250-252, 2022

DOI for Previous history of hyperthyroidism in emergency department patients with atrial fibrillation does not increase the risk of thromboembolism and death

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Sjölin, Karl; Aulin, Julia; Wallentin, Lars; Eriksson, Niclas et al.

Part of Journal of the American Heart Association, 2022

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Carnicelli, Anthony P.; Hong, Hwanhee; Connolly, Stuart J.; Eikelboom, John et al.

Part of Circulation, p. 242-255, 2022

DOI for Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Aulin, Julia; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Part of American Heart Journal, p. 13-24, 2022

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Piccini, Jonathan P.; Caso, Valeria; Connolly, Stuart J.; Fox, Keith A. A. et al.

Part of The Lancet, p. 1383-1390, 2022

DOI for Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

Gorog, Diana A; Gue, Ying X; Chao, Tze-Fan; Fauchier, Laurent et al.

Part of Europace, p. 1844-1871, 2022

DOI for Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Hijazi, Ziad; Benz, Alexander P.; Lindbäck, Johan; Alexander, John H. et al.

Part of European Heart Journal, p. 208-218, 2022

Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data

de Belder, Mark A; Deanfield, John; James, Stefan; Oldgren, Jonas

Part of European Heart Journal - Quality of Care and Clinical Outcomes, p. 801-803, 2022

DOI for Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data

Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized clinical trials

Gargiulo, Giuseppe; Cannon, Christopher P; Gibson, C Michael; Goette, Andreas et al.

Part of European Heart Journal - Cardiovascular Pharmacotherapy, 2021

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Carnicelli, Anthony P; Hong, Hwanhee; Giugliano, Robert P; Connolly, Stuart J et al.

Part of American Heart Journal, p. 48-58, 2021

DOI for Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial.

Zeymer, Uwe; Leiva, Orly; Hohnloser, Stefan H; Steg, Philippe Gabriel et al.

Part of EuroIntervention, p. 474-480, 2021

DOI for Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial.

LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry

Johnson, Linda S. B.; Oldgren, Jonas; Barrett, Tyler W.; McNaughton, Candace D. et al.

Part of Journal of the American Heart Association, 2021

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Steffel, Jan; Collins, Ronan; Antz, Matthias; Cornu, Pieter et al.

Part of Europace, p. 1612-1676, 2021

DOI for 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction

Jönelid, Birgitta; Christersson, Christina; Hedberg, Pär; Leppert, Jerzy et al.

Part of Scandinavian Journal of Clinical and Laboratory Investigation, p. 353-360, 2021

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Part of Cardiovascular Research, p. 2112-2123, 2021

Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Benz, Alexander P.; Healey, Jeff S.; Chin, Ashley; Commerford, Patrick et al.

Part of Cardiovascular Research, p. 295-304, 2021

DOI for Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference

Fabritz, Larissa; Crijns, Harry J. G. M.; Guasch, Eduard; Goette, Andreas et al.

Part of Europace, p. 329-344, 2021

DOI for Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Part of Circulation, p. 1863-1873, 2021

DOI for Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)

Eccleston, David S.; Kim, Joseph M.; ten Berg, Jurien M.; Steg, P. Gabriel et al.

Part of Clinical Cardiology, p. 1002-1010, 2021

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

Peterson, Benjamin E.; Bhatt, Deepak L.; Steg, Ph Gabriel; Oldgren, Jonas et al.

Part of JACC, p. 768-780, 2021

Risk markers of incident atrial fibrillation in patients with coronary heart disease

Tomasdottir, Maria; Held, Claes; Hadziosmanovic, Nermin; Westerbergh, Johan et al.

Part of American Heart Journal, p. 92-101, 2021

Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Siegbahn, Agneta; Lindbäck, Johan; Hijazi, Ziad; Åberg, Mikael et al.

Part of Journal of Thrombosis and Haemostasis, p. 2726-2737, 2021

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Oldgren, Jonas; Laurila, Sanna; Åkerblom, Axel; Latva-Rasku, Aino et al.

Part of Diabetes, obesity and metabolism, p. 1505-1517, 2021

DOI for Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study

Weight gain and blood pressure

Sundström, Johan; Lind, Lars; Lampa, Erik; Angerås, Oskar et al.

Part of Journal of Hypertension, p. 387-394, 2020

DOI for Weight gain and blood pressure

Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study

Östgren, Carl J; Söderberg, Stefan; Festin, Karin; Angerås, Oskar et al.

Part of European Journal of Preventive Cardiology, p. 250-259, 2020

Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic

Mohammad, Moman A.; Koul, Sasha; Olivecrona, Göran K.; Götberg, Matthias et al.

Part of Heart, p. 1812-1818, 2020

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial

Berry, Natalia C.; Mauri, Laura; Steg, Philippe Gabriel; Bhatt, Deepak L. et al.

Part of Circulation. Cardiovascular Interventions, 2020

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Part of JAMA Network Open, 2020

DOI for Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Kloosterman, Marielle; Oldgren, Jonas; Conen, David; Wong, Jorge A. et al.

Part of Europace, p. 870-877, 2020

DOI for Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Hijazi, Ziad; Wallentin, Lars; Lindbäck, Johan; Alexander, John H. et al.

Part of Journal of the American Heart Association, 2020

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

Steg, Philippe Gabriel; Ducrocq, Gregory; Bhatt, Deepak L; Hohnloser, Stefan H et al.

Part of Journal of the American College of Cardiology, p. 238-240, 2020

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Part of Journal of Thrombosis and Haemostasis, p. 2287-2295, 2020

Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial

Berglund, Erik; Wallentin, Lars; Oldgren, Jonas; Renlund, Henrik et al.

Part of European Journal of Preventive Cardiology, p. 1311-1319, 2020

Comparison of Dabigatran Plus a P2Y₁₂ Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.

De Caterina, Raffaele; Procopio, Antonio; Lopez Sendon, José-Luis; Raev, Dimitar et al.

Part of American Journal of Medicine, p. 1302-1312, 2020

Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care

Elfwen, Ludvig; Lagedal, Rickard; Rubertsson, Sten; James, Stefan et al.

Part of IJC Heart & Vasculature, 2020

Comparison of the Effect of Age (< 75 Versus >= 75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

ten Berg, Jurrien M.; Steg, Philippe Gabriel; Bhatt, Deepak L.; Hohnloser, Stefan H. et al.

Part of American Journal of Cardiology, p. 735-743, 2020

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial

Nicolau, Jose C.; Bhatt, Deepak L.; Hohnloser, Stefan H.; Kimura, Takeshi et al.

Part of Drugs, p. 995-1005, 2020

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

McAlister, Finlay A.; Mian, Rajibul; Oldgren, Jonas; Wallentin, Lars et al.

Part of PLOS ONE, 2020

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin, Lars; Lindbäck, Johan; Eriksson, Niclas; Hijazi, Ziad et al.

Part of European Heart Journal, p. 4037-4046, 2020

DOI for Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)-An initial pilot-study of a randomized clinical trial

Elfwen, Ludvig; Lagedal, Rickard; Nordberg, Per; James, Stefan et al.

Part of Resuscitation, p. 253-261, 2019

DOI for Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)-An initial pilot-study of a randomized clinical trial

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Oldgren, Jonas; Steg, Philippe Gabriel; Hohnloser, Stefan H.; Lip, Gregory Y. H. et al.

Part of European Heart Journal, p. 1553-1562, 2019

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Hohnloser, Stefan H.; Steg, Philippe Gabriel; Oldgren, Jonas; Nickenig, Georg et al.

Part of JACC, p. 1553-1561, 2019

DOI for Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

Lip, Gregory Y. H.; Mauri, Laura; Montalescot, Gilles; Ozkor, Mick et al.

Part of American Heart Journal, p. 13-22, 2019

DOI for Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Part of Journal of the American Heart Association, 2019

Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Part of Clinical Cardiology, p. 1003-1009, 2019

Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease

Jönelid, Birgitta; Kragsterman, Björn; Berglund, Lars; Andrén, Bertil et al.

Part of JRSM Cardiovascular Disease, p. 1-9, 2019

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes

Maeng, Michael; Steg, Philippe Gabriel; Bhatt, Deepak L.; Hohnloser, Stefan H. et al.

Part of JACC, p. 2346-2355, 2019

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

ten Berg, Jurrien M.; de Veer, Anne; Oldgren, Jonas; Steg, Philippe Gabriel et al.

Part of JACC, p. 2331-2341, 2019

DOI for Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome

Batra, Gorav; Ahlsson, Anders; Lindahl, Bertil; Lindhagen, Lars et al.

Part of Upsala Journal of Medical Sciences, p. 70-77, 2019

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Lip, Gregory Y H; Bhatt, Deepak L; Hohnloser, Stefan H; Kimura, Takeshi et al.

Part of Journal of the American College of Cardiology, p. 2431-2433, 2019

DOI for Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients - a description of the DAPACARD study

Åkerblom, Axel; Oldgren, Jonas; Latva-Rasku, Aino; Johansson, Lars et al.

Part of Upsala Journal of Medical Sciences, p. 59-64, 2019

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Part of Europace, p. 1231-1242, 2018

DOI for The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Kent, Anthony P.; Brueckmann, Martina; Fraessdorf, Mandy; Connolly, Stuart J. et al.

Part of Journal of the American College of Cardiology, p. 255-267, 2018

DOI for Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Ezekowitz, Michael D.; Pollack, Charles V.; Halperin, Jonathan L.; England, Richard D. et al.

Part of European Heart Journal, p. 2959-2971, 2018

DOI for Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival

Elfwen, Ludvig; Lagedal, Rickard; James, Stefan K; Jonsson, Martin et al.

Part of American Heart Journal, p. 90-95, 2018

DOI for Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival

Förstahandsvalet som strokeprevention vid förmaksflimmer: Randomiserade studier med >70 000 patienter har visat på fördelarna med NOAK

Oldgren, Jonas

Part of Läkartidningen, 2018

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial

Avezum, Alvaro; de Figueiredo Oliveira, Gustavo Bernardes; Diaz, Rafael; Gonzalez Hermosillo, Jesus Antonio et al.

Part of Open heart, 2018

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation: The authors reply

Cannon, Christopher P.; Lip, Gregory Y. H.; Oldgren, Jonas

Part of New England Journal of Medicine, p. 485-486, 2018

DOI for Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation: The authors reply

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Part of American Heart Journal, p. 169-177, 2018

DOI for Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Hijazi, Ziad; Pol, Tymon; Oldgren, Jonas; Lindbäck, Johan et al.

Part of Journal of the American College of Cardiology, p. 506-506, 2018

New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Part of Journal of the American College of Cardiology, p. 330-330, 2018

DOI for New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study

Lagedal, Rickard; Elfwén, Ludvig; James, Stefan K; Oldgren, Jonas et al.

Part of American Heart Journal, p. 53-61, 2018

DOI for Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Part of European Heart Journal, p. 1330-1393, 2018

DOI for The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

Steffel, Jan; Verhamme, Peter; Potpara, Tatjana S.; Albaladejo, Pierre et al.

Part of Kardiologia polska, p. 1283-1298, 2018

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha, Dipak; Breithardt, Günter; Camm, A John; Lip, Gregory Y H et al.

Part of Europace, p. 395-407, 2018

Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study"

Oldgren, Jonas; Sundström, Johan

Part of Circulation, p. 2313-2313, 2018

DOI for Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study"

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Part of European Heart Journal, p. 477-485, 2018

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan K et al.

Part of European Heart Journal - Cardiovascular Pharmacotherapy, p. 36-45, 2018

DOI for Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Part of Journal of Internal Medicine, p. 282-292, 2018

DOI for Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation

Friberg, Leif; Oldgren, Jonas

Part of Open heart, 2017

Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Lund, Lars H; Oldgren, Jonas; James, Stefan

Part of Current Heart Failure Reports, p. 59-70, 2017

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of European Heart Journal, p. 2137-2149, 2017

DOI for Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Part of Journal of the American Heart Association, 2017

DOI for Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study

Sjögren, Vilhelm; Byström, Björn; Renlund, Henrik; Svensson, Peter J. et al.

Part of PLOS ONE, 2017

DOI for Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

Åsberg, Signild; Hijazi, Ziad; Norrving, Bo; Terént, Andreas et al.

Part of Trials, 2017

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Part of American Heart Journal, p. 94-103, 2017

DOI for Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Cannon, Christopher P.; Bhatt, Deepak L.; Oldgren, Jonas; Lip, Gregory Y. H. et al.

Part of New England Journal of Medicine, p. 1513-1524, 2017

DOI for Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

Christersson, Christina; Lindahl, Bertil; Berglund, Lars; Siegbahn, Agneta et al.

Part of Upsala Journal of Medical Sciences, p. 224-233, 2017

Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study

Sundström, Johan; Hedberg, Jakob; Thuresson, Marcus; Aarskog, Pernilla et al.

Part of Circulation, p. 1183-1192, 2017

DOI for Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study

Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Oldgren, Jonas; Steg, Philippe-Gabriel; Hohnloser, Stefan H.; Lip, Gregory Y. et al.

Part of Circulation, 2017

2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

Kirchhof, Paulus; Benussi, Stefano; Kotecha, Dipak; Ahlsson, Anders et al.

Part of Revista espanola de cardiologia (English ed.), 2017

DOI for 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

Essebag, Vidal; Proietti, Riccardo; Birnie, David H.; Wang, Jia et al.

Part of Europace, p. 1630-1636, 2017

DOI for Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Batra, Gorav; Lindhagen, Lars; Andell, Pontus; Erlinge, David et al.

Part of Journal of the American Heart Association, 2017

Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Part of Journal of the American College of Cardiology, p. 327-327, 2017

DOI for Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Effects of dabigatran according to age in atrial fibrillation

Lauw, Mandy N.; Eikelboom, John W.; Coppens, Michiel; Wallentin, Lars et al.

Part of Heart, p. 1015-1023, 2017

DOI for Effects of dabigatran according to age in atrial fibrillation

External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John et al.

Part of Journal of the American College of Cardiology, p. 879-879, 2016

The ABC risk score for patients with atrial fibrillation Reply

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Siegbahn, Agneta et al.

Part of The Lancet, p. 1980-1981, 2016

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial

Ezekowitz, Michael D.; Pollack, Charles V.; Sanders, Paul; Halperin, Jonathan L. et al.

Part of American Heart Journal, p. 59-68, 2016

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Ezekowitz, Michael D.; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A. et al.

Part of Europace, p. 973-978, 2016

DOI for Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Efficacy And Safety Of Non-Vitamin K Oral Anticoagulants (NOAC) Compared With Warfarin At Its Best In Patients With Atrial Fibrillation

Oldgren, Jonas; Friberg, L.

Part of International Journal of Stroke, p. 46-46, 2016

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

Batra, Gorav; Andell, P.; Erlinge, D.; James, Stefan et al.

Part of European Heart Journal, p. 1387-1387, 2016

DOI for Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction

All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Batra, Gorav; Svennblad, Bodil; Held, Claes; Jernberg, Tomas et al.

Part of Heart, p. 926-933, 2016

DOI for All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Cannon, Christopher P.; Gropper, Savion; Bhatt, Deepak L.; Ellis, Stephen G. et al.

Part of Clinical Cardiology, p. 555-564, 2016

Dabigatran etexilate and reduction in serum apolipoprotein B

Joseph, Philip; Pare, Guillaume; Wallentin, Lars; Connolly, Stuart et al.

Part of Heart, p. 57-62, 2016

DOI for Dabigatran etexilate and reduction in serum apolipoprotein B

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Part of EUROPEAN HEART JOURNAL, p. 47-47, 2016

D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Siegbahn, Agneta; Oldgren, Jonas; Andersson, Ulrika; Ezekowitz, Michael D et al.

Part of Thrombosis and Haemostasis, p. 921-930, 2016

DOI for D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John et al.

Part of Journal of the American College of Cardiology, p. 893-893, 2016

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H et al.

Part of Circulation, p. 1697-1707, 2016

DOI for Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

Kirchhof, Paulus; Breithardt, Guenter; Bax, Jeroen; Benninger, Gerlinde et al.

Part of Europace, p. 37-50, 2016

DOI for A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

Eriksson, Niclas; Wallentin, Lars; Berglund, Lars; Axelsson, Tomas et al.

Part of Pharmacogenomics (London), p. 1425-1439, 2016

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Alexander, John H.; Hanna, Michael et al.

Part of European Heart Journal, p. 1582-1590, 2016

DOI for The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Part of The Lancet, p. 2302-2311, 2016

DOI for The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial

Ezekowitz, M. D.; Connolly, S. J.; Fraessdorf, M.; Brueckmann, M. et al.

Part of European Heart Journal, p. 862-862, 2015

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Brambatti, Michela; Darius, Harald; Oldgren, Jonas; Clemens, Andreas et al.

Part of International Journal of Cardiology, p. 127-131, 2015

DOI for Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Douketis, J D; Healey, J S; Brueckmann, M; Eikelboom, J W et al.

Part of Thrombosis and Haemostasis, p. 625-632, 2015

DOI for Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Westenbrink, B. D.; Alings, M.; Connolly, S. J.; Eikelboom, J. et al.

Part of Journal of Thrombosis and Haemostasis, p. 699-707, 2015

DOI for Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Szummer, K; Oldgren, Jonas; Lindhagen, Lars; Carrero, J J et al.

Part of Journal of the American Medical Association (JAMA), p. 707-716, 2015

DOI for Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Part of Journal of the American College of Cardiology, 2015

DOI for Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Part of Journal of the American College of Cardiology, 2015

DOI for Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of Europace, p. 1467-1507, 2015

DOI for Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Part of American Heart Journal, p. 1151-1160, 2015

DOI for Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Oldgren, Jonas; Healey, Jeff S.; Ezekowitz, Michael; Commerford, Patrick et al.

Part of Circulation, p. 1568-1576, 2014

DOI for Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Part of Circulation, 2014

DOI for Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Part of Circulation, p. 961-970, 2014

DOI for Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Part of Heart, p. 1193-1200, 2014

DOI for Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of Europace, p. 149-150, 2014

DOI for Authors' response: from monitoring to vigilance about patient adherence to new oral anticoagulants

Author reply: To PMID 23625942

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of Europace, p. 151-152, 2014

DOI for Author reply: To PMID 23625942

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Granger, Christopher B et al.

Part of European Heart Journal, p. 1475-1480, 2013

DOI for Biomarkers in atrial fibrillation: a clinical review

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of Europace, p. 625-651, 2013

DOI for European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

Hedberg, Jakob; Sundström, Johan; Thuresson, M.; Aarskog, P. et al.

Part of Journal of Internal Medicine, p. 371-380, 2013

DOI for Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Eikelboom, John W.; Connolly, Stuart J.; Hart, Robert G.; Wallentin, Lars et al.

Part of Journal of the American College of Cardiology, p. 900-908, 2013

DOI for Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

Dans, Antonio L; Connolly, Stuart J; Wallentin, Lars; Yang, Sean et al.

Part of Circulation, p. 634-640, 2013

DOI for Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary

Heidbuchel, Hein; Verhamme, Peter; Alings, Marco; Antz, Matthias et al.

Part of European Heart Journal, p. 2094-2106, 2013

DOI for EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Connolly, Stuart J.; Wallentin, Lars; Ezekowitz, Michael D.; Eikelboom, John et al.

Part of Circulation, p. 237-243, 2013

DOI for The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

"Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

Healey, Jeff S.; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Part of Circulation, 2013

DOI for "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Oldgren, Jonas; Wallentin, Lars; Alexander, John H; James, Stefan et al.

Part of European Heart Journal, p. 1670-1680, 2013

Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Hijazi, Ziad; Oldgren, Jonas; Wallentin, Lars; Andersson, Ulrika et al.

Part of Circulation, 2013

DOI for Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

Davidson, Thomas; Husberg, Magnus; Janzon, Magnus; Oldgren, Jonas et al.

Part of European Heart Journal, p. 177-183, 2013

DOI for Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Paré, Guillaume; Eriksson, Niclas; Lehr, Thorsten; Connolly, Stuart et al.

Part of Circulation, p. 1404, 2013

DOI for Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Healey, Jeff S; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Part of Circulation, 2013

DOI for Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Part of Circulation, p. 1605-1616, 2012

DOI for Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Eikelboom, John W.; Connolly, Stuart J.; Healey, Jeff S.; Yang, Sean et al.

Part of Circulation, 2012

DOI for Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Hohnloser, Stefan H.; Oldgren, Jonas; Yang, Sean; Wallentin, Lars et al.

Part of Circulation, p. 669-676, 2012

DOI for Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Healey, Jeff S.; Eikelboom, John; Douketis, James; Wallentin, Lars et al.

Part of Circulation, p. 343-348, 2012

DOI for Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial

Connolly, Stuart J.; Reilly, Paul A.; Pogue, Janice; Eikelboom, John et al.

Part of Circulation, p. 2793-2793, 2012

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Eikelboom, John W.; Wallentin, Lars; Connolly, Stuart J.; Ezekowitz, Mike et al.

Part of Circulation, p. 2363-2372, 2011

DOI for Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion

Nagarakanti, Rangadham; Ezekowitz, Michael D.; Oldgren, Jonas; Yang, Sean et al.

Part of Circulation, p. 131-136, 2011

DOI for Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion

Treatment with an Oral Direct Thrombin Inhibitor Decreases Platelet Activity but Increases Markers of Inflammation in Patients with Myocardial Infarction.

Christersson, Christina; Oldgren, Jonas; Wallentin, Lars; Siegbahn, Agneta

Part of Journal of Internal Medicine, p. 215-223, 2011

DOI for Treatment with an Oral Direct Thrombin Inhibitor Decreases Platelet Activity but Increases Markers of Inflammation in Patients with Myocardial Infarction.

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS(2) Score: A Subgroup Analysis of the RE-LY Trial

Oldgren, Jonas; Alings, Marco; Darius, Harald; Diener, Hans-Christoph et al.

Part of Annals of Internal Medicine, p. 660-667, 2011

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Oldgren, Jonas; Budaj, Andrzej; Granger, Christopher B.; Khder, Yasser et al.

Part of European Heart Journal, p. 2781-2789, 2011

DOI for Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Myeloperoxidase is not useful for the early assessment of patients with chest pain

Eggers, Kai M.; Dellborg, Mikael; Johnston, Nina; Oldgren, Jonas et al.

Part of Clinical Biochemistry, p. 240-245, 2010

DOI for Myeloperoxidase is not useful for the early assessment of patients with chest pain

Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Oldgren, Jonas; Wernroth, Lisa; Stenestrand, Ulf

Part of Heart, p. 1451-1457, 2010

DOI for Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Wallentin, Lars; Yusuf, Salim; Ezekowitz, Michael D.; Alings, Marco et al.

Part of The Lancet, p. 975-983, 2010

DOI for Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Åkerblom, Axel; James, Stefan K.; Koutouzis, Michail; Lagerqvist, Bo et al.

Part of Journal of the American College of Cardiology, p. 470-475, 2010

DOI for Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Koutouzis, Michael; Lagerqvist, Bo; Oldgren, Jonas; Åkerblom, Axel et al.

Part of Clinical Cardiology, p. 686-692, 2010

DOI for Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Thompson, Alexander; Gao, Pei; Orfei, Lia; Watson, Sarah et al.

Part of The Lancet, p. 1536-1544, 2010

DOI for Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery

Alström, Ulrica; Granath, Fredrik; Oldgren, Jonas; Ståhle, Elisabeth et al.

Part of Thrombosis Research, p. 572-577, 2009

DOI for Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

Ezekowitz, Michael D.; Connolly, Stuart; Parekh, Amit; Reilly, Paul A. et al.

Part of American Heart Journal, p. 805-810, 2009

DOI for Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

Fortfarande stor anledning till entusiasm över ett nytt strokeförebyggande läkemedel

Oldgren, Jonas

Part of Läkartidningen, p. 3020-3021, 2009

Dabigatran versus warfarin in patients with atrial fibrillation

Connolly, Stuart J.; Ezekowitz, Michael D.; Yusuf, Salim; Eikelboom, John et al.

Part of New England Journal of Medicine, p. 1139-1151, 2009

DOI for Dabigatran versus warfarin in patients with atrial fibrillation

Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

Eggers, Kai M.; Lagerqvist, Bo; Oldgren, Jonas; Venge, Per et al.

Part of American Heart Journal, p. 588-594, 2008

DOI for Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

Risk prediction in chest pain patients by biochemical markers including estimates of renal function

Eggers, Kai; Dellborg, Mikael; Oldgren, Jonas; Swahn, Eva et al.

Part of International Journal of Cardiology, p. 207-213, 2008

DOI for Risk prediction in chest pain patients by biochemical markers including estimates of renal function

Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial

Tangelder, Marco J. D.; Frison, Lars; Weaver, Douglas; Wilcox, Robbert G. et al.

Part of American Heart Journal, p. 382-7, 2008

DOI for Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

Peters, Ron J. G.; Joyner, Campbell; Bassand, Jean-Pierre; Afzal, Rizwan et al.

Part of European Heart Journal, p. 324-331, 2008

DOI for The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

Oldgren, Jonas; Wallentin, Lars; Afzal, Rizwan; Bassand, Jean-Pierre et al.

Part of European Heart Journal, p. 315-23, 2008

DOI for Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

Xa inhibition and coagulation activity: the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

Oldgren, Jonas; Johnston, Nina; Siegbahn, Agneta

Part of American Heart Journal, p. 4930, 2008

DOI for Xa inhibition and coagulation activity: the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischemic events: Observations from the ESTEEM trial

Christersson, Christina; Oldgren, Jonas; Bylock, Anders; Siegbahn, Agneta et al.

Part of European Heart Journal, p. 692-698, 2007

DOI for Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischemic events: Observations from the ESTEEM trial

Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients

Eggers, Kai; Ellenius, Johan; Dellborg, Mikael; Groth, Torgny et al.

Part of International Journal of Cardiology, p. 366-374, 2007

DOI for Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

Oldgren, Jonas; James, Stefan; Siegbahn, Agneta; Wallentin, Lars

Part of European Heart Journal, p. 699-704, 2007

DOI for Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: Reply

Christersson, Christina; Oldgren, Jonas; Bylock, Anders; Siegbahn, Agneta et al.

Part of European Heart Journal, p. 1783-1783, 2007

DOI for Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: Reply

The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment

Alström, Ulrica; Tydén, Hans; Oldgren, Jonas; Siegbahn, Agneta et al.

Part of Thrombosis Research, p. 353-359, 2007

DOI for The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment

Risk prediction in patients with chest pain: early assessment by the combination of troponin I results and electrocardiographic findings

Eggers, Kai M.; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Part of Coronary Artery Disease, p. 181-9, 2005

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone

Eggers, Kai M.; Oldgren, Jonas; Nordensköld, Anna; Lindahl, Bertil

Part of Coronary Artery Disease, p. 315-9, 2005

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

Oldgren, Jonas; Fellenius, C.; Boman, K.; Jansson, J-H. et al.

Part of Journal of Internal Medicine, p. 420-7, 2005

DOI for Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

James, Stefan K; Oldgren, Jonas; Lindbäck, Johan; Johnston, Nina et al.

Part of American Heart Journal, p. 619-626, 2005

DOI for An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

Christersson, Christina; Oldgren, Jonas; Bylock, A.; Wallentin, Lars et al.

Part of Journal of Thrombosis and Haemostasis, p. 2245-53, 2005

DOI for Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone.

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Part of Coronary Artery Disease, p. 315-319, 2005

Analytical performance of a new point of care instrument for measurement of cardiac markers - an evaluation under clinical conditions

Eggers, K M; Oldgren, J; Berg, A; Lindahl, B

Part of Point of Care, 2005

Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines

Johansson, Jakob; Hammerby, Rutger; Oldgren, Jonas; Rubertsson, Sten et al.

Part of Acta Anaesthesiologica Scandinavica, p. 909-913, 2004

DOI for Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines

Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Part of American Heart Journal, p. 574-581, 2004

DOI for Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

Diagnostic value of serial measurement of cardiac markers in patients with chest pain.: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction.

Eggers, Kai; Oldgren, Jonas; Nordenskjöld, Anna; Lindahl, Bertil

Part of American Heart Journal, p. 574-581, 2004

Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.

Oldgren, Jonas; Siegbahn, Agneta; Grip, Lars; Linder, Rikard et al.

Part of Thromb Haemost, p. 381-7, 2004

Myocardial Damage, Inflammation and Thrombin Inhibition in Unstable Coronary Artery Disease

Oldgren, Jonas; Wallentin, Lars; Grip, L; Linder, R et al.

Part of European Heart Journal, p. 86-93, 2003

DOI for Myocardial Damage, Inflammation and Thrombin Inhibition in Unstable Coronary Artery Disease

Biomarkers in addition to clinical characteristics for prediction of peripheral artery disease in patients with recent myocardial infarction

Jönelid, Birgitta; Christersson, Christina; Hedberg, P; Leppert, Jerzy et al.

Publications

Recent publications

All publications

Articles in journal

Articles, review/survey

Conference papers

Manuscripts (preprints)